Business Context and Reporting Period
ImmunityBio, Inc. (IBRX) filed a Form 8-K on May 28, 2021, reporting the entry into a material definitive agreement. The Company, incorporated in Delaware and headquartered in San Diego, California, is an emerging growth company focused on pharmaceutical and manufacturing activities.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a lease amendment. Key financial terms of the agreement include:
- Base Rent: Approximately $170,400 per month for the Expansion Premises.
- Rent Escalation: 3% annual increase effective April 1 of each year.
- Tenant Improvement Allowance: Approximately $2.6 million for the buildout of the Expansion Premises.
- Variable Expenses: Company responsible for its share of property taxes and operating expenses.
Material Changes
On May 28, 2021, the Company entered into a First Amendment to Lease with 605 Nash, LLC, a related party owned by Executive Chairman and principal stockholder Dr. Patrick Soon-Shiong. The amendment, effective April 1, 2021, significantly expanded the Company's facility footprint:
- Space Increase: Added 57,760 square feet (Expansion Premises) to the original 6,883 square feet, totaling 64,643 square feet.
- Location: 605-607 Nash Street, El Segundo, California.
- Lease Term: Initial term for Expansion Premises runs from April 2021 through March 2028. The Original Premises term was extended to March 2028.
- Extension Option: Option to extend the Combined Premises for an additional three-year term through March 2031.
Outlook, Management Commentary, and Risks
Management Commentary: The Company plans to utilize the Combined Premises to build a full-scale manufacturing facility, including clean rooms for upstream and downstream manufacturing and fill-finish capabilities. This expansion is intended to increase capacity and scale production for product candidates, including its COVID-19 vaccine and booster.
Risks and Contingencies: The filing identifies a related-party transaction risk, as the landlord is owned by the Company's Executive Chairman. The Company bears the costs associated with the buildout of the Combined Premises, subject to the $2.6 million allowance.
Investor Verification Checklist
- Verify the total capital expenditure required for the buildout beyond the $2.6 million tenant improvement allowance.
- Confirm the related-party transaction disclosures and approval processes regarding the lease with 605 Nash, LLC.
- Review the full text of the Amendment filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2021.
- Assess the impact of the increased fixed and variable lease costs on the Company's cash burn rate.